ALFA Finder India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold Telegram alerts alfafinder.com →
Monday, 16 November 2026 NSE & BSE filings, as they land
ALFA News Straight from the exchange filing
Regulatory Approval

Biocon Receives US FDA Approval for Pebrilzo Breast Cancer Biosimilar

Biocon Biologics has secured U.S. FDA approval for Pebrilzo, a biosimilar to the reference drug Perjeta, expanding its oncology portfolio to five approved biosimilars in the United States. Following a global settlement with Genentech, the company has established a commercial pathway for an American launch by the third quarter of 2028.

Close-up of a scientist examining algae in a petri dish, highlighting biotechnology research. Stock photo illustrating Biocon's regulatory approval story.
Photo: Chokniti Khongchum / Pexels
Key numbers
Market Cap ₹59,329 CrMid-range Performer
TTM Revenue ₹17,414 CrOperating Revenue
P/E Ratio 131.2xSector 43.7x
1Yr Change -10.31%Price Performance

Key highlights

  • FDA approval granted for Pebrilzo (pertuzumab-qcay) injection for HER2-positive breast cancer
  • Product serves as a biosimilar to the reference biologic Perjeta (pertuzumab)
  • Global settlement with Genentech secures a U.S. launch date in Q3 of calendar year 2028
  • Approval marks Biocon's fifth oncology biosimilar to receive regulatory clearance in the U.S.
  • Previously received positive CHMP opinion in Europe for marketing authorization in September 2026

Biocon Expands US Oncology Presence with Pebrilzo Approval

Biocon Limited has achieved a regulatory milestone with the U.S. Food and Drug Administration's approval of Pebrilzo, a monoclonal antibody designed to treat HER2-positive breast cancer. The drug works by blocking HER2 receptors on cancer cells, providing a biosimilar alternative to the established reference product Perjeta.

This approval is supported by a comprehensive analytical and clinical data package demonstrating no clinically meaningful differences in safety, quality, or efficacy between the biosimilar and the reference biologic. The addition of Pebrilzo reinforces the company's anti-cancer portfolio, targeting a disease that affects approximately 320,000 women diagnosed with breast cancer annually in the United States.

Settlement with Genentech Defines Commercial Launch Timeline

While the FDA has granted regulatory clearance, the commercialization of Pebrilzo in the United States is governed by a global settlement and license agreement with Genentech. Under this agreement, Biocon has secured an earliest licensed launch window for the third quarter of calendar year 2028. This follows earlier international progress, including a patent settlement announced in October 2026 that allows for a much earlier launch in Europe and the United Kingdom by the first quarter of 2027.

Additionally, the company previously secured a ten-year partnership in Brazil for the same molecule valued at approximately 400 million US dollars, with supplies expected to commence in the fourth quarter of fiscal year 2027.

Financial Performance and Strategic Pipeline Growth

The regulatory milestone comes as Biocon navigates a challenging financial period. For the quarter ended September 30, 2026, the company reported operating revenue of 4,388.9 crore, representing a modest 2.2 percent growth over the previous year. However, net profit for the quarter declined by 51.1 percent year-on-year to 41.3 crore.

Despite current volatility, management has guided for accelerated revenue and profitability in the second half of fiscal 2027. The company's oncology strategy remains focused on long-term growth, with a pipeline that includes proposed biosimilars for nivolumab and pembrolizumab, alongside existing approved products like Ogivri and Fulphila.

Biocon · share price, past month

Biocon Oncology Portfolio and Pipeline Highlights

  • Ogivri (trastuzumab-dkst) for HER2-directed therapy
  • Jobevne (bevacizumab-nwgd) for various cancer indications
  • Fulphila (pegfilgrastim-jmdb) for neutropenia management
  • Aukelso (denosumab-kyqq) recently added to the oncology list
  • Proposed biosimilars to trastuzumab/hyaluronidase in development
  • Immuno-oncology pipeline focusing on nivolumab and pembrolizumab

Executive Perspective on Biosimilar Access

The U.S. FDA approval of PEBRILZO, our biosimilar pertuzumab, marks another significant milestone in Biocon’s journey to expand access to high-quality biosimilars. As our fifth oncology biosimilar to receive U.S. FDA approval, PEBRILZO strengthens our anti-cancer portfolio and advances our commitment to expanding access to high-quality, affordable biologic medicines.

— Shreehas Tambe, CEO and Managing Director, Biocon Limited
Earlier announcements by Biocon
DateAnnouncementAmount
25 Sep 2026UK MHRA approval for new drug product fill-finish unit for Semglee (insulin glargine) at Malaysia facilitySource: biocon.com–
25 Aug 2026Japan MHLW marketing approval for Pegfilgrastim biosimilarSource: biocon.com–
18 Aug 2026US FDA supplemental approval for Yesintek (ustekinumab-kfce) single-dose prefilled autoinjectorSource: biocon.com–
29 Jul 2026Health Canada approval for Yesintek (ustekinumab) autoinjector penSource: biocon.com–
16 Jul 2026European Medicines Agency (EMA) approval for new drug product fill-finish unit for insulins at Malaysia facilitySource: biocon.com–
11 May 2026Health Canada approval for Micafungin for Injection USP (50 mg and 100 mg)Source: biocon.com–

What to watch next

  • Earliest licensed launch of Pebrilzo in Europe and UK in Q1 CY 2027
  • Scheduled announcement of Q3 FY27 quarterly financial results on February 4, 2027
  • Commencement of pertuzumab supplies in Brazil starting Q4 FY27
  • Planned commercial launch of Pebrilzo in the United States in Q3 2028
Biocon · financial snapshot
Share price₹364.05
Market capitalisation₹59,329.01 Cr
Revenue (annual)₹16,927.00 Cr
Net profit (annual)₹385.60 Cr
Revenue (latest quarter)₹4,388.90 Cr+1.22% vs previous quarter
Net profit (latest quarter)₹41.30 Cr-70.73% vs previous quarter
P/E (TTM)131.23×Sector 43.74×
Promoter holding44.68%0.00% QoQ
FII holding8.64%Current quarter

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

Exchange filing by Biocon Limited announcing US FDA approval for Pebrilzo biosimilar. Market figures from a third-party data provider.

Read the filing ↗
All Biocon filings and newsView all → Every Biocon announcement on ALFA FilingsSee filings →

More from Biocon

All →

More in Approvals

All →